Furthermore, the SGLT2 inhibitor group demonstrated a statistically significant reduction in heart failure exacerbations, all-cause mortality, all-cause rehospitalization/emergency department visits, and new-onset atrial fibrillation/flutter [54]. This evidence concerns the gene SLC5A2 and atrial fibrillation.